<DOC>
	<DOCNO>NCT01566487</DOCNO>
	<brief_summary>This open label , randomise , balance , two-treatment , two-period , two-sequence , crossover , multicentric experimental bioequivalence study .</brief_summary>
	<brief_title>Bioequivalence Study Quetiapine Fumarate Tablets 300 mg Under Fasting Condition</brief_title>
	<detailed_description>The objective study compare bioavailability characterise pharmacokinetics profile sponsor formulation Quetiapine fumarate tablet 300 mg Dr. Reddy 's Laboratories Limited , India respect reference formulation Seroquel tablets 300 mg Astrazeneca Pharmaceuticals , USA adult schizophrenia patient fast condition . 54 subject dose enrol study .</detailed_description>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Written inform consent participation study patient Patient 's Legally Acceptable Representative ( LAR ) . If patient his/her legally acceptable representative unable read/write impartial witness present entire inform consent process must append his/her signature consent form . Schizophrenic patient , 18 55 year age ( inclusive ) . Patient document clinical diagnosis stable schizophrenia ( DSM IVTR ) control stable 300 mg Quetiapine regimen give 12hour interval least 2 week prior first dose , confirm Principal Investigator Having Body Mass Index ( BMI ) 18 35 ( inclusive ) . calculate weight kg/height m2 . Not significant disease clinically significant abnormal finding except schizophrenia screening , medical history , physical examination , laboratory evaluation , 12lead ECG recording Chest X ray ( Posteroanterior view ) . The investigator must ensure respective hepatic , renal , haematopoietic , cardiac respiratory function appropriate include patient study . Able comply study procedure opinion investigator . In case female patient serum pregnancy test screen visit must negative . Sexually active woman , unless surgically sterile ( least 6 month prior Study drug administration ) postmenopausal least 12 consecutive month , must use effective method avoid pregnancy ( include oral , transdermal , implanted contraceptive [ hormonal method conjunction secondary method ] , intrauterine device , female condom spermicide . diaphragm spermicide.Absolute sexual abstinence , use condom spermicide sexual partner sterile [ least 6 month prior Study drug administration ] sexual partner ) least 4 week prior study drug administration , study 30 day last dose study drug . Cessation birth control point discuss responsible physician . ( It investigator 's responsibility ensure point regard effective method avoid pregnancy discuss patient/LAR detail patient agree document source document . The investigator ensure patient use effective method avoid pregnancy per protocol ) . In case Male patient : Either partner patient must use effective method avoid pregnancy least 4 week prior study drug administration , study 30 day last dose study drug . Cessation birth control point discuss responsible physician . ( It investigator 's responsibility ensure point regard effective method avoid pregnancy discuss patient/LAR detail patient agree document source document . The investigator ensure patient use effective method avoid pregnancy per protocol ) . Known hypersensitivity/allergy idiosyncratic reaction Quetiapine excipients . Clinically significant illness ( include hypotensive episode systemic infection ) surgery within 4 week prior first dose . Current relevant history serious . severe unstable psychiatric illness ( Meeting criterion ( Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSMIV ) AXIS I ) except schizophrenia . History syncope orthostatic hypotension Ingestion medication list time 10 day first study drug administration . In case Patient selection discretion Principal Investigator . Following list permissible medication , provide , patient stable regimen least I0 day prior throughout study . Alprazolam , Fluoxetin , Imipramine , Haloperidol , Risperidone . ( Refer Appendix 4 list nonpermissible medication ) A history alcohol drug dependence DSMIV criterion within 6 month prior screen . Smokers smoke 10 10 cigarette/day inability abstain smoking study Donation blood ( ≥ 1 unit 350 mL ) within 90 day prior receive first dose study medication study . Note : In case blood loss less equol 200 mL ; patient may dose 60 day blood donation . A positive hepatitis screen include hepatitis B surface antigen HCV antibody . Positive test HIV infection . ECG abnormality ( clinically relevant ) , vital sign abnormality ( systolic blood pressure low 90 140 mnHg , diastolic blood pressure low 50 90 mmHg patient antihypertensive medication heart rate less 50 100 bpm ) significant orthostatic hypotension ( i.e.. drop systolic blood pressure 30 mmHg and/or drop diastolic blood pressure 20 mmHg stand ) screen . Patients vital sign value 5 % specify range consider stable could include study discretion investigator . Any condition1 Abnormal baseline finding investigator 's judgement might increase risk patient decrease chance obtain satisfactory data need obtain objective study . The receipt investigational product participation drug research study within period 30 day prior first dose study medication . Note : Elimination halflife study drug take consideration inclusion Patient study . Psychosis judge direct physiological effect abuse medication substance . Positive test drug abuse ( amphetamine , barbiturate , benzodiazepine , cocaine , morphine , marijuana ) do urine scan Screening . ( Except alprazolam permissible medication ) . Known history Organic Brain Disorder . Hospitalisation exacerbation schizophrenia within two month prior screen screen period . Patients , opinion investigator , pose imminent risk suicide danger self others Patients follow cardiac condition exclude : Recent myocardial infarction ( &lt; I2 month ) QTc prolongation ( screen electrocardiogram QTc &gt; 450 msec men , QTc &gt; 470 msec woman ) History QTc prolongation use concomitant medication prolong QTc interval Sustained cardiac arrhythmia history sustain cardiac arrhythmia Uncompensated congestive heart failure Complete leave bundle branch block Firstdegree heart block PR interval &gt; 0.22 second Presence cataract Ophthalmoscopic examination ( slit lamp exam ) . History agranulocytosis . Known case Diabetes mellitus fast blood glucose ≥126 mg/dl screen visit . Clinically significant history presence gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , liver kidney disease ( e.g , hepatic insufficiency ) , condition know interfere absorption , distribution , metabolism , excretion drug . Concurrent Parkinson 's disease Clinically significant history cataract , tardive dyskinesia . neuroleptic malignant syndrome . epilepsy seizure . Any clinically relevant neurological , endocrinal . cardiovascular . cerebrovascular , pulmonary , hematological , immunologic disease could lead safety risk patient upon participation trial could interfere conduct trial Any reason , opinion Investigator , would prevent patient participate study . Patients abnormal thyroid function test screen visit judge Investigator could lead safety risk patient upon participation trial could Interfere conduct trial . Patient hyperprolactinemia screen visit judge Investigator could lead safety risk patient upon participation trial could interfere conduct trial . Dementia related psychosis . Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Quetiapine fumarate</keyword>
	<keyword>crossover</keyword>
</DOC>